• Je něco špatně v tomto záznamu ?

Oncological outcome of surgical management in patients with recurrent uterine cancer-a multicenter retrospective cohort study-CEEGOG EX01 Trial

A. Germanova, F. Raspagliesi, L. Chiva, L. Dusek, M. Arvas, E. Leblanc, T. Lengeyl, V. Di Donato, A. Zaal, P. Dursun, I. Zapardiel, T. Turan, SA. Triginelli, SW. Kim, V. Chiappa, F. Martinelli, J. Slama, G. Bogani, R. Kocian, D. Cibula,

. 2019 ; 29 (4) : 711-720. [pub] -

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006391
E-zdroje Online Plný text

NLK ProQuest Central od 2001-01-01 do Před 6 měsíci
Health & Medicine (ProQuest) od 2001-01-01 do Před 6 měsíci

Odkazy

PubMed 31064862
DOI 10.1136/ijgc-2019-000292
Knihovny.cz E-zdroje

OBJECTIVES: To assess the survival of patients who have received an operation for recurrent cervical and endometrial cancer and to determine prognostic variables for improved oncologic outcome. METHODS: A retrospective multicenter analysis of the medical records of 518 patients with cervical (N = 288) or endometrial cancer (N = 230) who underwent surgery for disease recurrence and who had completed at least 1 year of follow-up. RESULTS: The median survival reached 57 months for patients with cervical cancer and 113 months for patients with endometrial cancer after surgical treatment of recurrence (p = 0.036). Histological sub-type had a significant impact on overall survival, with the best outcome in endometrial endometrioid cancer (121 months), followed by cervical squamous cell carcinoma, cervical adenocarcinoma, or other types of endometrial cancer (81 vs 35 vs 35 months; p <0.001). The site of recurrence did not significantly influence survival in cervical or in endometrial cancer. Cancer stage at first diagnosis, tumor grade, lymph node status at recurrence, progression-free interval after first diagnosis, and free resection margins were associated with improved overall survival on univariate analysis. On multivariate analysis, the stage at first diagnosis and resection margins were significant independent predictive parameters of an improved oncologic outcome. CONCLUSION: Long-term survival can be achieved via secondary cytoreductive surgery in selected patients with recurrent cervical and endometrial cancer. An excellent outcome is possible even if the recurrence site is located in the lymph nodes. The possibility of achieving complete resection should be the main criterion for patient selection.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006391
003      
CZ-PrNML
005      
20200518132612.0
007      
ta
008      
200511s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/ijgc-2019-000292 $2 doi
035    __
$a (PubMed)31064862
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Germanova, Anna $u Department of Obstetrics and Gynecology, Gynecologic Oncology Center, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic ena.german@gmail.com.
245    10
$a Oncological outcome of surgical management in patients with recurrent uterine cancer-a multicenter retrospective cohort study-CEEGOG EX01 Trial / $c A. Germanova, F. Raspagliesi, L. Chiva, L. Dusek, M. Arvas, E. Leblanc, T. Lengeyl, V. Di Donato, A. Zaal, P. Dursun, I. Zapardiel, T. Turan, SA. Triginelli, SW. Kim, V. Chiappa, F. Martinelli, J. Slama, G. Bogani, R. Kocian, D. Cibula,
520    9_
$a OBJECTIVES: To assess the survival of patients who have received an operation for recurrent cervical and endometrial cancer and to determine prognostic variables for improved oncologic outcome. METHODS: A retrospective multicenter analysis of the medical records of 518 patients with cervical (N = 288) or endometrial cancer (N = 230) who underwent surgery for disease recurrence and who had completed at least 1 year of follow-up. RESULTS: The median survival reached 57 months for patients with cervical cancer and 113 months for patients with endometrial cancer after surgical treatment of recurrence (p = 0.036). Histological sub-type had a significant impact on overall survival, with the best outcome in endometrial endometrioid cancer (121 months), followed by cervical squamous cell carcinoma, cervical adenocarcinoma, or other types of endometrial cancer (81 vs 35 vs 35 months; p <0.001). The site of recurrence did not significantly influence survival in cervical or in endometrial cancer. Cancer stage at first diagnosis, tumor grade, lymph node status at recurrence, progression-free interval after first diagnosis, and free resection margins were associated with improved overall survival on univariate analysis. On multivariate analysis, the stage at first diagnosis and resection margins were significant independent predictive parameters of an improved oncologic outcome. CONCLUSION: Long-term survival can be achieved via secondary cytoreductive surgery in selected patients with recurrent cervical and endometrial cancer. An excellent outcome is possible even if the recurrence site is located in the lymph nodes. The possibility of achieving complete resection should be the main criterion for patient selection.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a přežívající onkologičtí pacienti $7 D000073116
650    _2
$a kohortové studie $7 D015331
650    _2
$a cytoredukční chirurgie $x metody $7 D065426
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a lokální recidiva nádoru $x mortalita $x patologie $x chirurgie $7 D009364
650    _2
$a staging nádorů $7 D009367
650    _2
$a prognóza $7 D011379
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a záchranná terapie $x metody $7 D016879
650    _2
$a míra přežití $7 D015996
650    _2
$a výsledek terapie $7 D016896
650    _2
$a nádory děložního čípku $x mortalita $x patologie $x chirurgie $7 D002583
650    _2
$a nádory dělohy $x mortalita $x patologie $x chirurgie $7 D014594
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Raspagliesi, Francesco $u Fondazione IRCCS, IstitutoNazionale dei Tumori, Milan, Italy.
700    1_
$a Chiva, Luis $u Department of Gynecologic Oncology, MD Anderson Cancer Center, Madrid, Spain.
700    1_
$a Dusek, Ladislav $u Institute for Biostatistics and Analyses, Masaryk University, Brno, Czech Republic.
700    1_
$a Arvas, Macit $u Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey.
700    1_
$a Leblanc, Eric $u Département de Cancérologie Gynécologique, Oscar Lambret Center, Lille, France.
700    1_
$a Lengeyl, Tibor $u Department of Gynecologic Oncology, National Cancer Institute, Bratislava, Slovakia.
700    1_
$a Di Donato, Violante $u Department of Gynecology,Obstetrics and Urology, Sapienza University of Rome, Rome, Italy.
700    1_
$a Zaal, Afra $u Department of Gynecological Oncology, University Medical Center Utrecht, Utrecht, Netherlands.
700    1_
$a Dursun, Polat $u Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Baskent University Schoolof Medicine, Ankara, Turkey.
700    1_
$a Zapardiel, Ignacio $u Gynecologic Oncology, La Paz University Hospital, Madrid, Spain.
700    1_
$a Turan, Taner $u Division of Gynecologic Oncology, Department ofObstetrics and Gynecology, Etlik Zubeyde Hanim Womens Health Research and Teaching Hospital, Ankara, Turkey.
700    1_
$a Triginelli, Sergio Augusto $u Division of Women's Health, Federal University of Minas Gerais, Belo Horizonte, Brazil.
700    1_
$a Kim, Sang Wun $u Department ofObstetrics and Gynecology, Institute of Women'sLife Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.
700    1_
$a Chiappa, Valentina $u Fondazione IRCCS, IstitutoNazionale dei Tumori, Milan, Italy.
700    1_
$a Martinelli, Fabio $u Fondazione IRCCS, IstitutoNazionale dei Tumori, Milan, Italy.
700    1_
$a Slama, Jiri $u Department of Obstetrics and Gynecology, Gynecologic Oncology Center, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Bogani, Giorgio $u Fondazione IRCCS, IstitutoNazionale dei Tumori, Milan, Italy.
700    1_
$a Kocian, Roman $u Department of Obstetrics and Gynecology, Gynecologic Oncology Center, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Cibula, David $u Department of Obstetrics and Gynecology, Gynecologic Oncology Center, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic.
773    0_
$w MED00009896 $t International journal of gynecological cancer : official journal of the International Gynecological Cancer Society $x 1525-1438 $g Roč. 29, č. 4 (2019), s. 711-720
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31064862 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200518132612 $b ABA008
999    __
$a ok $b bmc $g 1525249 $s 1096447
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 29 $c 4 $d 711-720 $e - $i 1525-1438 $m International journal of gynecological cancer $n Int J Gynecol Cancer $x MED00009896
LZP    __
$a Pubmed-20200511
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace